Filtered By:
Source: Cardiology Journal
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 265 results found since Jan 2013.
Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR study
CONCLUSIONS: Among AF patients anticoagulated with rivaroxaban, HF patients had a worse clinical profile and a higher MACE risk and cardiovascular mortality. HF was independently associated with the development of MACE, but not with thromboembolic events or major bleeding.PMID:36200548 | DOI:10.5603/CJ.a2022.0091
Source: Cardiology Journal - October 6, 2022 Category: Cardiology Authors: Manuel Anguita S ánchez Francisco Mar ín Jaime Masjuan Juan Cos ín-Sales Jos é Manuel Vázquez Rodríguez Vivencio Barrios Gonzalo Bar ón-Esquivias I ñaki Lekuona Alejandro I P érez-Cabeza Rom án Freixa-Pamias Francisco Javier Parra Jimenez Mohame Source Type: research
Should targeted temperature management be used in cardiogenic shock patients? Systematic review and meta-analysis
CONCLUSIONS: The present analysis shows no significant benefit of TTM in patients with CS. Moreover, no statistically significant increase of the incidence of adverse effects was found. However, further randomized studies with higher sample size and greater validity are needed to determine if TTM is worth implementing in CS patients.PMID:36200546 | DOI:10.5603/CJ.a2022.0093
Source: Cardiology Journal - October 6, 2022 Category: Cardiology Authors: Adam Nieborek Jerzy R Ladny Milosz J Jaguszewski Andrea Denegri Aleksandra Sikora Szymon Pucylo Aleksandra Gasecka Michal Pruc Ivan Savytsky Lukasz Szarpak Source Type: research
The impact of first wave of the SARS-CoV-2 2019 pandemic in Poland on characteristics and outcomes of patients hospitalized due to stable coronary artery disease
CONCLUSIONS: The SARS-CoV-2 2019 pandemic affected the characteristics and hospitalization course of stable angina patients hospitalized following the first wave. The hospitalization outcome was similar in the analyzed time intervals. The higher prevalence of comorbidities raises concern regarding upcoming years.PMID:36200545 | DOI:10.5603/CJ.a2022.0094
Source: Cardiology Journal - October 6, 2022 Category: Cardiology Authors: Justyna Jankowska-Sanetra Krzysztof Sanetra Marta Konopko Monika Kutowicz Magdalena Synak Krzysztof Milewski Pawe ł Kaźmierczak Łukasz Kołtowski Piotr P Buszman Source Type: research
Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR study
CONCLUSIONS: Among AF patients anticoagulated with rivaroxaban, HF patients had a worse clinical profile and a higher MACE risk and cardiovascular mortality. HF was independently associated with the development of MACE, but not with thromboembolic events or major bleeding.PMID:36200548 | DOI:10.5603/CJ.a2022.0091
Source: Cardiology Journal - October 6, 2022 Category: Cardiology Authors: Manuel Anguita S ánchez Francisco Mar ín Jaime Masjuan Juan Cos ín-Sales Jos é Manuel Vázquez Rodríguez Vivencio Barrios Gonzalo Bar ón-Esquivias I ñaki Lekuona Alejandro I P érez-Cabeza Rom án Freixa-Pamias Francisco Javier Parra Jimenez Mohame Source Type: research
Should targeted temperature management be used in cardiogenic shock patients? Systematic review and meta-analysis
CONCLUSIONS: The present analysis shows no significant benefit of TTM in patients with CS. Moreover, no statistically significant increase of the incidence of adverse effects was found. However, further randomized studies with higher sample size and greater validity are needed to determine if TTM is worth implementing in CS patients.PMID:36200546 | DOI:10.5603/CJ.a2022.0093
Source: Cardiology Journal - October 6, 2022 Category: Cardiology Authors: Adam Nieborek Jerzy R Ladny Milosz J Jaguszewski Andrea Denegri Aleksandra Sikora Szymon Pucylo Aleksandra Gasecka Michal Pruc Ivan Savytsky Lukasz Szarpak Source Type: research
The impact of first wave of the SARS-CoV-2 2019 pandemic in Poland on characteristics and outcomes of patients hospitalized due to stable coronary artery disease
CONCLUSIONS: The SARS-CoV-2 2019 pandemic affected the characteristics and hospitalization course of stable angina patients hospitalized following the first wave. The hospitalization outcome was similar in the analyzed time intervals. The higher prevalence of comorbidities raises concern regarding upcoming years.PMID:36200545 | DOI:10.5603/CJ.a2022.0094
Source: Cardiology Journal - October 6, 2022 Category: Cardiology Authors: Justyna Jankowska-Sanetra Krzysztof Sanetra Marta Konopko Monika Kutowicz Magdalena Synak Krzysztof Milewski Pawe ł Kaźmierczak Łukasz Kołtowski Piotr P Buszman Source Type: research
Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR study
CONCLUSIONS: Among AF patients anticoagulated with rivaroxaban, HF patients had a worse clinical profile and a higher MACE risk and cardiovascular mortality. HF was independently associated with the development of MACE, but not with thromboembolic events or major bleeding.PMID:36200548 | DOI:10.5603/CJ.a2022.0091
Source: Cardiology Journal - October 6, 2022 Category: Cardiology Authors: Manuel Anguita S ánchez Francisco Mar ín Jaime Masjuan Juan Cos ín-Sales Jos é Manuel Vázquez Rodríguez Vivencio Barrios Gonzalo Bar ón-Esquivias I ñaki Lekuona Alejandro I P érez-Cabeza Rom án Freixa-Pamias Francisco Javier Parra Jimenez Mohame Source Type: research
Should targeted temperature management be used in cardiogenic shock patients? Systematic review and meta-analysis
CONCLUSIONS: The present analysis shows no significant benefit of TTM in patients with CS. Moreover, no statistically significant increase of the incidence of adverse effects was found. However, further randomized studies with higher sample size and greater validity are needed to determine if TTM is worth implementing in CS patients.PMID:36200546 | DOI:10.5603/CJ.a2022.0093
Source: Cardiology Journal - October 6, 2022 Category: Cardiology Authors: Adam Nieborek Jerzy R Ladny Milosz J Jaguszewski Andrea Denegri Aleksandra Sikora Szymon Pucylo Aleksandra Gasecka Michal Pruc Ivan Savytsky Lukasz Szarpak Source Type: research
The impact of first wave of the SARS-CoV-2 2019 pandemic in Poland on characteristics and outcomes of patients hospitalized due to stable coronary artery disease
CONCLUSIONS: The SARS-CoV-2 2019 pandemic affected the characteristics and hospitalization course of stable angina patients hospitalized following the first wave. The hospitalization outcome was similar in the analyzed time intervals. The higher prevalence of comorbidities raises concern regarding upcoming years.PMID:36200545 | DOI:10.5603/CJ.a2022.0094
Source: Cardiology Journal - October 6, 2022 Category: Cardiology Authors: Justyna Jankowska-Sanetra Krzysztof Sanetra Marta Konopko Monika Kutowicz Magdalena Synak Krzysztof Milewski Pawe ł Kaźmierczak Łukasz Kołtowski Piotr P Buszman Source Type: research
Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR study
CONCLUSIONS: Among AF patients anticoagulated with rivaroxaban, HF patients had a worse clinical profile and a higher MACE risk and cardiovascular mortality. HF was independently associated with the development of MACE, but not with thromboembolic events or major bleeding.PMID:36200548 | DOI:10.5603/CJ.a2022.0091
Source: Cardiology Journal - October 6, 2022 Category: Cardiology Authors: Manuel Anguita S ánchez Francisco Mar ín Jaime Masjuan Juan Cos ín-Sales Jos é Manuel Vázquez Rodríguez Vivencio Barrios Gonzalo Bar ón-Esquivias I ñaki Lekuona Alejandro I P érez-Cabeza Rom án Freixa-Pamias Francisco Javier Parra Jimenez Mohame Source Type: research
Should targeted temperature management be used in cardiogenic shock patients? Systematic review and meta-analysis
CONCLUSIONS: The present analysis shows no significant benefit of TTM in patients with CS. Moreover, no statistically significant increase of the incidence of adverse effects was found. However, further randomized studies with higher sample size and greater validity are needed to determine if TTM is worth implementing in CS patients.PMID:36200546 | DOI:10.5603/CJ.a2022.0093
Source: Cardiology Journal - October 6, 2022 Category: Cardiology Authors: Adam Nieborek Jerzy R Ladny Milosz J Jaguszewski Andrea Denegri Aleksandra Sikora Szymon Pucylo Aleksandra Gasecka Michal Pruc Ivan Savytsky Lukasz Szarpak Source Type: research
The impact of first wave of the SARS-CoV-2 2019 pandemic in Poland on characteristics and outcomes of patients hospitalized due to stable coronary artery disease
CONCLUSIONS: The SARS-CoV-2 2019 pandemic affected the characteristics and hospitalization course of stable angina patients hospitalized following the first wave. The hospitalization outcome was similar in the analyzed time intervals. The higher prevalence of comorbidities raises concern regarding upcoming years.PMID:36200545 | DOI:10.5603/CJ.a2022.0094
Source: Cardiology Journal - October 6, 2022 Category: Cardiology Authors: Justyna Jankowska-Sanetra Krzysztof Sanetra Marta Konopko Monika Kutowicz Magdalena Synak Krzysztof Milewski Pawe ł Kaźmierczak Łukasz Kołtowski Piotr P Buszman Source Type: research
Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR study
CONCLUSIONS: Among AF patients anticoagulated with rivaroxaban, HF patients had a worse clinical profile and a higher MACE risk and cardiovascular mortality. HF was independently associated with the development of MACE, but not with thromboembolic events or major bleeding.PMID:36200548 | DOI:10.5603/CJ.a2022.0091
Source: Cardiology Journal - October 6, 2022 Category: Cardiology Authors: Manuel Anguita S ánchez Francisco Mar ín Jaime Masjuan Juan Cos ín-Sales Jos é Manuel Vázquez Rodríguez Vivencio Barrios Gonzalo Bar ón-Esquivias I ñaki Lekuona Alejandro I P érez-Cabeza Rom án Freixa-Pamias Francisco Javier Parra Jimenez Mohame Source Type: research
Should targeted temperature management be used in cardiogenic shock patients? Systematic review and meta-analysis
CONCLUSIONS: The present analysis shows no significant benefit of TTM in patients with CS. Moreover, no statistically significant increase of the incidence of adverse effects was found. However, further randomized studies with higher sample size and greater validity are needed to determine if TTM is worth implementing in CS patients.PMID:36200546 | DOI:10.5603/CJ.a2022.0093
Source: Cardiology Journal - October 6, 2022 Category: Cardiology Authors: Adam Nieborek Jerzy R Ladny Milosz J Jaguszewski Andrea Denegri Aleksandra Sikora Szymon Pucylo Aleksandra Gasecka Michal Pruc Ivan Savytsky Lukasz Szarpak Source Type: research
The impact of first wave of the SARS-CoV-2 2019 pandemic in Poland on characteristics and outcomes of patients hospitalized due to stable coronary artery disease
CONCLUSIONS: The SARS-CoV-2 2019 pandemic affected the characteristics and hospitalization course of stable angina patients hospitalized following the first wave. The hospitalization outcome was similar in the analyzed time intervals. The higher prevalence of comorbidities raises concern regarding upcoming years.PMID:36200545 | DOI:10.5603/CJ.a2022.0094
Source: Cardiology Journal - October 6, 2022 Category: Cardiology Authors: Justyna Jankowska-Sanetra Krzysztof Sanetra Marta Konopko Monika Kutowicz Magdalena Synak Krzysztof Milewski Pawe ł Kaźmierczak Łukasz Kołtowski Piotr P Buszman Source Type: research
